TIBET PHARMA(SH:600211)2020-04-27 16:00Financial Performance - Net profit attributable to shareholders increased by 81.75% to CNY 128,531,405.96 compared to the same period last year[13] - Basic earnings per share rose by 87.18% to CNY 0.73 compared to the same period last year[13] - The weighted average return on equity increased by 2.00 percentage points to 5.11% compared to the same period last year[13] - Total operating revenue for Q1 2020 was approximately CNY 296.78 million, a slight decrease from CNY 297.08 million in Q1 2019, representing a decline of 0.1%[48] - Net profit for Q1 2020 was CNY 129.30 million, compared to CNY 71.37 million in Q1 2019, reflecting an increase of 81.5%[50] - The total profit for Q1 2020 was CNY 143.35 million, compared to CNY 79.72 million in Q1 2019, an increase of 79.9%[48] Assets and Liabilities - Total assets increased by 4.31% to CNY 2,886,409,917.73 compared to the end of the previous year[13] - The total assets reached ¥2,886,409,917.73, up from ¥2,767,231,426.91 year-over-year[34] - The total current assets as of March 31, 2020, amounted to ¥1,458,763,027.53, an increase from ¥1,341,034,746.27 in the previous year[34] - The company’s total liabilities included accounts payable of ¥8,208,884.22, down from ¥12,440,650.65, a decrease of approximately 34.00%[34] - Total liabilities decreased from 320,441,135.65 to 286,487,864.00, a reduction of approximately 10.5%[37] - The company’s total current liabilities increased from 61,124,279.01 to 72,181,531.93, an increase of about 18%[42] Cash Flow - Net cash flow from operating activities increased by 0.33% to CNY 138,364,960.42 compared to the same period last year[13] - Total cash inflow from operating activities reached CNY 455,131,479.01, up from CNY 333,568,834.09 in the previous year, indicating a growth of approximately 36.5%[54] - The net cash flow from investing activities increased by 56.82 million yuan, a growth of 200.57%, mainly due to an increase in the net amount of recovered structured deposits[23] - The net cash flow from investing activities was CNY 28,489,179.17, a turnaround from a negative cash flow of CNY -28,328,356.41 in Q1 2019[54] Shareholder Information - The total number of shareholders reached 16,510 by the end of the reporting period[16] - The top ten shareholders hold a combined 86.56% of the company's shares, with the largest shareholder owning 32.28%[16] - As of the reporting date, the major shareholder pledged 22.03 million shares, accounting for 12.44% of the total share capital[27] Research and Development - Research and development expenses decreased by 1.68 million yuan, a reduction of 57.49%, primarily due to decreased R&D expenses from a subsidiary[22] - Other income increased by 47.99 million yuan, a rise of 40,396.27%, mainly due to receiving industry development support funds[22] Capital and Equity - The company completed a capital increase, raising its total share capital from 177,098,459 shares to 247,937,843 shares[18] - Total equity increased from 2,446,790,291.26 to 2,599,922,053.73, reflecting a growth of around 6.2%[37] - The company's equity attributable to shareholders rose to CNY 2.24 billion in Q1 2020 from CNY 2.12 billion in Q1 2019, an increase of 5.8%[48] Other Financial Metrics - The company received government subsidies amounting to CNY 48,113,800.80 related to its normal business operations[15] - The company executed new revenue and leasing standards starting January 1, 2020, with no significant impact on total assets or liabilities[64] - The company has maintained its commitment to its financial strategies without any overdue commitments reported[32]